Phase 2
N=22
Effects of Liothyronine on Energy Expenditure and Cardiovascular Function
Healthy
Bottom Line
View on ClinicalTrials.gov: NCT03098433 ↗Enrolled (actual)
22
Serious AEs
0.0%
Results posted
Mar 2021
Primary outcome: Primary: Cardiac Output — -3.7; -1.4; 1 millilitres
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Liothyronine (Drug); Levothyroxine (Drug); Placebos (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Virginia Commonwealth University
- Primary completion
- Jun 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cardiac Output |
-3.7; -1.4; 1 | — |
| SECONDARY Energy Expenditure |
0.006; -0.05; -0.007 | — |
Summary
This study will assess the short term effects of a single dose of liothyronine on the cardiovascular system and energy expenditure
Eligibility Criteria
Inclusion Criteria
- BMI >20 0.5 2.5 x the upper laboratory reference limit
Data sourced from ClinicalTrials.gov (NCT03098433). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.